Vilde D Haakensen

Thoracic oncologist and cancer researcher. Teacher of Acem meditation.

[Vilde D Haakensen @vilded]

Another failure for TIGIT as a target as Skyscraper-03 failed to improve survival for pts undergoing CRT for NSCLC when adding anti-TIGIT to PD-L1-inh.

[Vilde D Haakensen @vilded]

So far, neoadjuvant chemo-IO is given to pts with respectable disease. But could it also be used for downstaging of borderline respectable disease? That is explored in the MDT-bridge trial. Borderline respectable pts where given 2 cycles before new MDT. 71% got surgery.

[Vilde D Haakensen @vilded]

Tarlatamab continues to impress. In the Dellphi 303 study where Tarlatamab was given with chemo and PD-L1 inhibitor from the start in 1L.
👉12m OS 81%
NB! Phase 1b non-randomised, n=96.
This promises a new era for our patients!

[Vilde D Haakensen @vilded]

Zongertinib and sevabertinib are both promising as HER2-TKIs also in 1L. Presented by Sanjay Popat and Xiuning Le. Awaiting results from phase 3 trials.

[Vilde D Haakensen @vilded]

No survival benefit of adding atezolizumab to CRT for SCLC-LD in the ACHIlES-Trial presented by Bjørn Henning Grønberg at #ASCO25 today. The discussant stressed the exceptionally good outcome in the control arm, the benefit of PCI and the possibly of twice-daily fractionation.

[Vilde D Haakensen @vilded]

CM816 viser nå signifikant overlevelse abb neoadjuvant kjemo-nivo sammenlignet med kjemo. Presentert av Patrick Frode på #ASCO25

[Vilde D Haakensen @vilded]

Prognostic value of FDG-PET before treatment with ipi/nivo +/- the UV1 vaccine for pts with mesothelioma. Congrats Solfrid Thunold! https://t.co/bB4Tt6ujIS

[Vilde D Haakensen @vilded]

@fkbmatrix @KjetilTasken @Oslounivsykehus @HellandAslaug @HRussnes @livefagereng Congratulations to both @KjetilTasken and Andras Kleppe!

[Vilde D Haakensen @vilded]

Åslaug Helland oppdaterer om IMPRESS-Norway på ASCO #ASCO24
https://t.co/z6hmZfcMTI

[Oslounivsykehus @Oslounivsykehus]

OUS får nøkkelrolle i stort europeisk kreftsamarbeid.
https://t.co/g1IXHNNp73 @KaasaStein

[Vilde D Haakensen @vilded]

Survival-data from the NIPU-trial randomising pts with pleural mesotheliom to double ICI alone or with telomerase vaccine UV1. https://t.co/bDDI3kXQbH

[Vilde D Haakensen @vilded]

Veldig gøy med positive resultater for NIPU-studien! Dataene presenteres på ESMO. @HellandAslaug @Ultimovacs

[HealthTalk @HealthTalkNorge]

Ultimovacs kunngjorde tirsdag kveld at det har vært en signifikant og klinisk relevant økning i totaloverlevelse blant pasienter med brysthinnekreft som mottok kreftvaksinen UV1 i fase 2-studien NIPU.
https://t.co/qoaNgpawOm

[Magne Nylenna @magnenylenna]

Nesten alene verdt Aftenposten-abonnementet. Ære være norsk presse!

[Kyte Group @GroupKyte]

Åslaug Helland fikk i dag overrakt Kong Olav´s kreftforskningspris av Kong Harald i Universitetets Aula. Gratulerer, Åslaug - vel fortjent!
@HellandAslaug

[Mina Gerhardsen @MinaGerhardsen]

Alkohol har en negativ effekt på hele 200 sykdommer. Gitt det er det en naturlig konsekvens at kostrådene, som er der for å ivareta hensyn til helsen, anbefaler avhold.

https://t.co/hY7YnNHrnI

[Vilde D Haakensen @vilded]

@HellandAslaug @DNVA1 @fkbmatrix Gratulerer!!

[Vilde D Haakensen @vilded]

@BHGronberg Great study with important information to all clinicians!! Do you have a screening-log indicating if the inclusion rate in your trial was different for older than younger patients?

[Vilde D Haakensen @vilded]

Great scientific input and lots of inspiration from excellent researchers: @MariamJHanjani @DouglasHanahan @Aslan_Tasdogan #CancerCrosslinks @OsloCancer